Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: A single-center experience with 68 patients

Blood

Volumn 113, Issue 11, 2009, Pages 2402-2409

  Tschudi, Martina ^a   Lämmle, Bernhard ^a   Alberio, Lorenzo ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; LEPIRUDIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BOLUS INJECTION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME;

EID: 63849194816     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-162271     Document Type: Article

References (17)

1. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol. 2006;133:259-269.
2. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-in-duced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133[suppl]:340-380.
3. Chilver-Stainer L, Lammle B, Alberio L. Titre of anti-heparin/PF4- antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems. Thromb Haemost. 2004;91:276-282.
4. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99:819- 829.
5. Gray E, Harenberg J. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J Thromb Haemost. 2005;3:2096-2097.
6. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1,HAT-2, and HAT-3. J Thromb Haemost. 2005;3: 2428-2436.
7. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000;96:2373-2378.
8. Hacquard M, de Maistre E, Lecompte T. Lepirudin: is the approved dosing schedule too high J Thromb Haemost. 2005;3:2593-2596.
9. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin- induced thrombocytopenia treated with lepirudin. Blood. 2006;108:1492-1496.
10. Tschudi M, Lämmle B, Alberio L. Dosing lepirudin in patients with heparin-induced thrombocytopenia and various degrees of renal function impairment [abstract]. J Thromb Haemost. 2007;5[suppl2]:PS673.
11. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121:535-555.
12. Alberio L, Kimmerle S, Baumann A, Mansouri Taleghani B, Demarmels Biasiutti F, Lämmle B. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med. 2003;114:528-536.
13. Alberio L. Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment. Curr Opin Hematol. 2008;15:456-464.
14. Meyer O, SalamaA, Pittet N, Schwind P. Rapid detection of heparin-induced platelet antibodies with particle gel immunoassay (ID-HPF4). Lancet. 1999;354:1525-1526.
15. Zürcher M, Sulzer I, Barizzi G, Lämmle B, Alberio L. Stability of coagulation assays performed in plasma from citrated whole blood transported at ambient temperature. Thromb Haemost. 2008;99:416-426.
16. Arzneimittel-Kompendium der Schweiz. Basel, Switzerland: Documed AG; 2008. www.kompendium.ch. Accessed June 2008.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.